Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank

Announces New $25 Million Credit Facility with Silicon Valley Bank

YORK-May 10, 2021-Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing

a pipeline of microdose array print (MAP ) therapeutics, today announced that the company has entered into a new $25 million credit

financing facility with Silicon Valley Bank (SVB).

non-dilutive credit facility provides us with a significant amount of financial and operating flexibility at terms that we believe

are favorable to the company," stated Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia.

"These funds will assist us in preparing for our anticipated Mydcombi launch, advancing the development of MicroLine, as

well as exploring additional ophthalmologic indications that could leverage our Optejet microdosing technology, all key elements

of our long-term growth strategy."

received $7.5 million upon closing of the facility. The remaining $17.5 million is available in two tranches and is accessed at

the company's option subject to the achievement of milestones.

are excited to support the Eyenovia team with this new financing facility as they continue to grow," said Clark Hayes, Managing

Director of Life Sciences and Healthcare at Silicon Valley Bank. "Eyenovia's microdose array print platform technology

is a key advancement in ocular pharmaceuticals and provides an efficient and precise alternative to conventional eyedroppers."

Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print

(MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia,

myopia progression and mydriasis. For more Information, visit www.eyenovia.com.

more than 35 years, Silicon Valley Bank (SVB) has helped innovative companies and their investors move bold ideas forward, fast.

SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial,

international and private banking services, SVB helps address the unique needs of innovators. Learn more at svb.com.

for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking

statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations,

strategies, predictions or any other statements relating to our future activities or other future events or conditions, including

estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations,

estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees

of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes

and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due

to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.

In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical

trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by

COVID-19 and resulting social distancing), timing, progress and results of such trials; the timing and our ability to submit applications

for, obtain and maintain regulatory approvals for our product candidates; the potential advantages of our product candidates and

platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding

the potential market opportunity for our product candidates; intellectual property risks; changes in legal, regulatory and legislative

environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for

our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and

except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any

forward-looking statements.

Chief Financial Officer

LifeSci Advisors, LLC

Pazanga Health Communications